미국 - 영어 - NLM (National Library of Medicine)

hospira, inc. - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 38 mg in 1 ml - gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine is indicated for patients previously treated with fluorouracil. gemcitabine is contraindicated in patients with a known hypersensitivity to gemcitabine. reactions include a

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

미국 - 영어 - NLM (National Library of Medicine)

mylan institutional llc - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 38 mg in 1 ml - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with fluorouracil. gemcitabine injection is contraindicated in patients with

미국 - 영어 - NLM (National Library of Medicine)

sagent pharmaceuticals - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 200 mg in 5 ml - gemcitabine for injection, usp in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine for injection, usp in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine for injection, usp in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine for injection, usp is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine for injection, usp is indicated for patients previously treated with fluorouracil. gemcitabine f

싱가포르 - 영어 - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - gemcitabine hcl 1144mg eqv gemcitabine - injection, powder, for solution - 1000mg - gemcitabine hcl 1144mg eqv gemcitabine 1000mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - gemcitabine hcl 230mg eqv gemcitabine - injection, powder, for solution - 200mg - gemcitabine hcl 230mg eqv gemcitabine 200mg

캐나다 - 영어 - Health Canada

hospira healthcare ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

캐나다 - 영어 - Health Canada

hospira healthcare ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

캐나다 - 영어 - Health Canada

hospira healthcare ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 2g - gemcitabine (gemcitabine hydrochloride) 2g - antineoplastic agents

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - gemcitabine hydrochloride 1140mg equivalent to 1000 mg gemcitabine;  ;   - powder for injection - 1000 mg - active: gemcitabine hydrochloride 1140mg equivalent to 1000 mg gemcitabine     excipient: mannitol nitrogen sodium acetate as sodium acetate trihydrate sodium hydroxide - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.